Goede resultaten eerste halfjaar, met stijgingspercentage van winst per aandeel in dubbele cijfers; verbeterde prognose voor jaarcijfers, ondanks tegenwind in tweede halfjaar

OSAKA, Japan–(BUSINESS WIRE)– Vergelijkbare omzet groeide met 6,7 procent, dankzij groeionderdelen van Takeda

• Vergelijkbare inkomsten stegen met 6,7 %, met solide resultaten in alle regio’s (VS +16.7%, Japan +0.3%, Europa & Canada +4.2%, Opkomende markten +3.4%). Groei-onderdelen Takeda (gastro-enterologie , Oncologie, centraal zenuwstelsel en opkomende markten) behielden sterk momentum voor groei van 14,9%.
  – Gastro-enterologie steeg met 24,8%, dankzij gegroeid marktaandeel ENTYVIO^® en TAKECAB^®.
  – Oncologie groeide 13,2% dankzij uitbreiding NINLARO^® en ADCETRIS^®, en de toevoeging van ICLUSIG en ALUNBRIG^TM.
  – Centraal zenuwstelsel groeide 26,7 %, met groei TRINTELLIX^® in VS van 58,7 %.
  – Opkomende markten groeien met 3,4 %, met groeipercentages in dubbele cijfers in Rusland en Brazilië, wat tijdelijke daling in China opvangt.
• Gerapporteerde omzet steeg met 3,6 %, waarbij groei-onderdelen van Takeda en gunstige wisselkoersen negatieve gevolgen afstotingen ruimschoots compenseren.

Takeda Reports First Half FY2017 Results

Strong first half performance with double-digit EPS growth;raising full-year outlook despite second half headwinds

OSAKA, Japan–(BUSINESS WIRE)– Underlying Revenue growth of 6.7% led by Takeda’s Growth Drivers

• Underlying Revenue grew +6.7% with solid performances across all regions (U.S. +16.7%, Japan +0.3%, Europe & Canada +4.2%, Emerging Markets +3.4%). Takeda’s Growth Drivers (GI, Oncology, CNS and Emerging Markets) maintained strong momentum to deliver growth of +14.9%.
  • GI (Gastroenterology) +24.8% fueled by market share growth of ENTYVIO^® and TAKECAB^®.
  • Oncology +13.2% driven by the expansion of NINLARO^® and ADCETRIS^®, and the addition of revenue from ICLUSIG^® and ALUNBRIG^TM.
  • CNS +26.7% with TRINTELLIX^® growing +58.7% in the U.S.
  • Emerging Markets +3.4% with strong double-digit growth in the key markets of Russia and Brazil offsetting a temporary decline in China.
• Reported revenue grew +3.6%, with the positive contribution from Takeda’s Growth Drivers and favorable currency impact (+2.4pp) more than offsetting the negative impact of divestitures (-5.5pp).

Double-digit EPS growth reflecting strong revenue growth and progress of Global Opex Initiative

• Underlying Core Earnings grew +44.4%, reflecting strong revenue growth and margin step up of 5.0pp (+2.7pp gross margin; +2.3pp from OPEX margin). First half earnings growth included some timing benefits.
• Reported operating profit was up +44.6%, driven mainly by strong Core Earnings growth. The first half result includes one-time gains of 136.8 billion yen, including the sale of shares held in Wako Pure Chemical Ltd., the sale of real estate, and the transfer of additional long-listed products to Teva Takeda Yakuhin Ltd.
• Underlying Core EPS was up +29.9%, and reported EPS increased +39.2% to 221 yen per share.

Net leverage improved due to steady progress on cash flow

• Year-to-date Operating Free Cash Flow increased +12.4% to 84.6 billion yen, and the disposal of non-core assets generated an additional 131 billion yen of cash.
• Net Debt / EBITDA dropped to 2.0x from 2.7x in March 2017.

Christophe Weber, Chief Executive Officer of Takeda, commented:
“Our Growth Drivers continued to deliver robust double-digit revenue growth, which together with our cost management initiatives led to a significant margin expansion. Furthermore, the ARIAD acquisition is delivering ahead of expectations, and the R&D transformation is well advanced. Although we expect headwinds in the second half of the year, we are still confident to raise our outlook for the full year as we execute against our key mid-term priorities of growing the portfolio, rebuilding the pipeline, and boosting profitability.”

Takeda raises its full-year outlook despite second half headwinds

• Increasing Management Guidance and Reported Forecast to reflect favorable year-to-date results. The Reported Forecast also benefits from lower impairment and restructuring expenses compared to the previous forecast.
• The majority of one-time gains were booked in the first half, and the majority of one-time expenses will be booked in the second half. The outlook also assumes loss of exclusivity of Velcade.
• Velcade estimates are based on the possible entry of 2 or 3 bortezomib-containing products in the U.S. from November 2017. Depending on various factors there may be an additional opportunity up to 30 billion yen, which will be partly reinvested in the business.

For more details on Takeda’s FY2017 first half results and other financial information, please visit https://www.takeda.com/investors/reports/

About Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its R&D efforts on oncology, gastroenterology and central nervous system therapeutic areas plus vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. New innovative products, especially in oncology and gastroenterology, as well as Takeda’s presence in Emerging Markets, are currently fueling the growth of Takeda. Around 30,000 Takeda employees are committed to improving quality of life for patients, working with Takeda’s partners in health care in more than 70 countries.
For more information, visit https://www.takeda.com/newsroom/.

View source version on businesswire.com: http://www.businesswire.com/news/home/20171031006703/en/

Contacts

Investor Relations
Takeda Pharmaceutical Company Limited
+81-(0)3-3278-2306
takeda.ir.contact@takeda.com
Media Relations
Takeda Pharmaceutical Company Limited
Tsuyoshi Tada, +81 (0)3-3278-2417
tsuyoshi.tada@takeda.com